Cantuzumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

Cantuzumab is a monoclonal antibody designed for the treatment of cancers. Also known as huC242 it binds the CanAg antigen.[1]

It is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates :

huC242 targets CanAg

"HuC242 binds to the extracellular domain of the tumor-associated carbohydrate antigen known as CanAg (a novel glycoform of MUC1). CanAg is strongly expressed in most pancreatic, biliary, and colorectal cancers. It is also expressed in a substantial proportion of gastric cancers (55%), uterine cancers (45%), non-small cell lung cancers (40%), and bladder cancers (40%)."[2]

References

  1. ↑ Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Rodon et al. 2008
  2. ↑ A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Helft et al. 2004

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Cantuzumab&oldid=4901392"